HyClone Laboratories, LLC (“HyClone”) filed a Motion to Quash in the U.S. District Court for the District of Utah, seeking to ...

The Global Women’s Health Market is expected to witness a growth rate of 4-5% in the next five years. Growing incidence of ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1] Celltrion previously received interchangeability (IC) designation for ...